Alpha Lipoic Acid: Dosage, Study Duration & Safety

01

What is it?

ALA is a vitamin-like redox cofactor

⁷

Alpha-lipoic acid, also called thioctic acid, is a vitamin-like organosulfur cofactor in mitochondrial dehydrogenase complexes. Supplements may contain racemic ALA or the R enantiomer, so form and labeled amount should be compared separately.

Neuropathy evidence is mixed

³

A 2024 Cochrane review found little or no effect on diabetic peripheral neuropathy symptoms or adverse events at six months; high attrition limited confidence. This is condition-specific evidence, not a general nootropic claim.

Direct nootropic evidence remains weak⁶

This profile does not identify adequate clinical evidence to rate ALA as a healthy-user cognitive or mental-energy supplement. Do not extrapolate condition-specific research to focus, memory, mood, or energy use.

02

Names, aliases and forms

Common Namesalpha-lipoic acid; R-lipoic acid

AbbreviationALA

Chemical Namesthioctic acid; 5-(dithiolan-3-yl)pentanoic acid; (R)-alpha-lipoic acid

Molecular FormulaC8H14O2S2

03

Mechanisms of action

Mitochondrial cofactor biology

⁷

Alpha-lipoic acid is a cofactor for mitochondrial dehydrogenase complexes. This chemistry identifies the ingredient but does not, by itself, establish a direct nootropic benefit.

04

Potential effects and evidence map

ALA human evidence is dominated by metabolic-disease and diabetic-neuropathy research. Cochrane (2024) found little or no effect on neuropathy symptoms or adverse events at six months, whereas a 2023 oral-ALA meta-analysis reported favorable symptom scores but no consistent benefit in several objective measures. This profile does not identify adequate direct healthy-user cognitive evidence.

Effect domainMagnitudeGrade

Cellular / long-term brain support⁶

CumulativeConfidence: Low

ALA has condition-specific redox and mitochondrial research, but it does not establish a healthy-user cognitive benefit.

Note This C grade reflects limited mixed human CNS evidence, not direct nootropic efficacy.

1/5

C

Mental energy / wakefulness⁶

UnknownConfidence: High

This profile assigns no healthy-user cognitive or mental-energy benefit because its cited research is condition-specific.

Note The cited research set concerns CNS disorders, neuropathy, or metabolic disease rather than a healthy-user nootropic indication.

0/5

E

05

Typical dosages and timing

Typical

600-1800 mg/day

Not a recommendation

Lower bound

600 mg/day

Profile value

Upper bound

1800 mg/day

Profile value

study context⁴600-1800 mg/day

The cited oral diabetic-polyneuropathy meta-analysis included 600, 1200, and 1800 mg/day subgroups. Study doses describe research exposure; they do not establish a personal-use regimen.

06

Timing & effect horizon

Effect horizonCumulative

Cumulative

Study window³Cumulative

6 months

Study window is cumulative³

The cited longer neuropathy trials assessed repeated daily oral use over months. That study window is not an acute-effect duration or a recommended cycle.

07

Safety, side effects and risk profile

Insulin autoimmune syndrome signal¹⁰

In 2021, EFSA concluded that ALA added to foods, including supplements, is likely to increase insulin autoimmune syndrome risk in people with certain genetic polymorphisms. EFSA could not determine a dose below which this risk would not occur and did not establish an incidence estimate.

Evidence uncertainty⁴

Confidence: High

The evidence is condition-specific and mixed; it does not establish a direct healthy-user cognitive benefit.

Note Keep metabolic-disease research separate from general nootropic marketing.

2/5

B

GI discomfort⁹

Confidence: High

A 2020 meta-analysis found no statistically significant placebo-adjusted increase in overall or gastrointestinal adverse events with ALA.

Note Individual intolerance can still occur.

1/5

B

Interaction risk¹¹

Confidence: Medium

A clinical reference advises people taking glucose-lowering medicines to discuss ALA use with their healthcare provider because ALA may also lower blood glucose.

Note This medication-use precaution is separate from the EFSA insulin autoimmune syndrome immune-risk signal.

2/5

C

Pregnancy / lactation caution⁹

Confidence: Medium

This profile does not draw a pregnancy or lactation safety conclusion from its general ALA tolerability evidence.

Note The cited placebo-controlled safety review informs general tolerability, not a pregnancy or lactation recommendation.

2/5

C

general tolerability⁹

A 2020 meta-analysis of 71 randomized placebo-controlled studies did not find a statistically significant increase in overall or gastrointestinal adverse events with ALA. This does not rule out individual intolerance or the EFSA insulin autoimmune syndrome signal.

08

Interactions and cautions

medication-use precaution¹¹

Memorial Sloan Kettering advises people taking medicines that lower blood glucose to speak with their healthcare provider before using ALA, because ALA may also lower blood glucose. This is distinct from the EFSA insulin autoimmune syndrome signal.

09

Legal and regulatory status

EFSA opinion¹⁰

For the European Union, the 2021 European Food Safety Authority opinion assessed ALA added to foods, including supplements, under the food-safety framework. It found a likely risk of insulin autoimmune syndrome in susceptible genetic subgroups and did not provide a dose below which risk would not occur. This is an EU safety assessment, not a global legal-status conclusion.

10

Practical buying and quality notes

Compare generic alpha-lipoic acid with R-lipoic acid only within the same labeled form. Then compare ALA milligrams, cost per gram or capsule, expiration or stability information, and independent testing; the R-form label identifies a distinct enantiomer and is not directly interchangeable with a racemic ALA label.²

11

FAQ

Is Alpha Lipoic Acid a nootropic?

⁶

Not as an established healthy-user cognitive supplement. This profile does not identify adequate clinical evidence to rate ALA for focus, memory, mood, or mental energy in healthy users.

How should I read the dosage range?

⁴

The profile card summarizes doses used in the cited oral research. Compare the labeled ALA amount and form, and do not treat a study range as a personal-use instruction.

Does ALA have an acute duration or cycle?

³

No reliable acute nootropic duration or cycle has been established. The cited evidence assesses repeated use over longer study windows, which is different from an effect-duration or cycle recommendation.

12

Alpha Lipoic Acid